Our Neurology team has a long tradition of revolutionizing stroke care through research. These trials, lead by our innovative team, have radically transformed the way stroke care is delivered around the world.

From NINDS Alteplase trials to DAWN


Since 1977 the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) has sponsored 28 phase 3 trials to evaluate treatments of stroke, which when all completed will have randomized a total of 44 862 patients in the United States and other countries.
Learn More

Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct


The effect of endovascular thrombectomy that is performed more than 6 hours after the onset of ischemic stroke is uncertain. Patients with a clinical deficit that is disproportionately severe relative to the infarct volume may benefit from late thrombectomy.
Learn More

Systemic THrombolysis Randomization IN Endovascular Stroke Therapy (SHRINE) Collaboration

Raul Nogueira | Emory University School Of Medicine

RESULTS: SHRINE collaboaration offers more data on non-inferiority of primary EVT over combined IVT+EVT in patients with large vessel occlusion strokes
Learn More

We have the expertise to support all sites in the most advanced treatment decisions, including extended window and decisions about thrombectomy.